Adult Tic Disorders Registry (RegisTICs)

The purpose of this study is to develop the adult tic disorders registry in order to characterize the relationship between tic severity and tic-related impairment in women compared to men with tic disorders.

Study Overview

• Status: Recruiting
• Conditions: Tic Disorders
• Intervention / Treatment: Other: QOL to be completed by the participant

• Study Type: Observational
• Enrollment (Estimated): 450

Contacts and Locations

• Study Contact: Name: Emmanuel Flamand-Roze, MD, PhD; Phone Number: +33 1 42 16 06 45; Email: emmanuel.flamand-roze@aphp.fr

Study Locations

• France
  • Clermont-Ferrand, France, 63003
    • Recruiting
    • CHU clermont-ferrand
    • Contact: Isabelle JALENQUES, MD; Phone Number: 0033 4 73 75 21 05; Email: ijalenques@chu-clermontferrand.fr
    • Principal Investigator: Isabelle JALENQUES, MD
  • Limoges, France, 87042
    • Recruiting
    • CHU Limoges
    • Principal Investigator: Jean-Luc HOUETO, MD
    • Contact: Jean-Luc HOUETO, MD; Phone Number: 0033 5 55 05 65 60; Email: jean-luc.houeto@chu-limoges.fr
  • Marseille, France, 13003
    • Recruiting
    • CHU Marseille
    • Contact: Tatiana WITJAS, MD; Phone Number: 0033 4 91 38 43 33; Email: Tatiana.WITJAS@ap-hm.fr
    • Principal Investigator: Tatiana WITJAS, MD
  • Paris, France, 75013
    • Recruiting
    • Service de Neurologie, GH Pitié Salpêtrière
    • Contact: Emmanuel FLAMAND-ROZE, MD; Phone Number: +33 01 42 16 24 81; Email: emmanuel.flamand-roze@aphp.fr
  • Poitiers, France, 86000
    • Recruiting
    • CHU Poitiers
    • Contact: Solène ANSQUER, MD; Phone Number: 0033 5 49 44 44 44; Email: solene.ansquer@chu-poitiers.fr
    • Principal Investigator: Solène ANSQUER, MD
  • Saint-Herblain, France, 44800
    • Recruiting
    • Chu Nantes
    • Contact: Philippe DAMIER, MD; Phone Number: 0033 2 40 16 52 12; Email: philippe.damier@chu-nantes.fr
    • Principal Investigator: Philippe DAMIER, MD
  • Strasbourg, France, 67200
    • Recruiting
    • CHU Strasbourg
    • Principal Investigator: Mathieu ANHEIM, MD
    • Contact: Mathieu ANHEIM, MD; Phone Number: 0033 3 88 12 85 85; Email: mathieu.anheim@chru-strasbourg.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patient with tics disorders

Description

Inclusion criteria :

1. Age >18 years
2. Patients with Tic disorders
3. Given the non-opposition

Non Inclusion criteria

1. No affiliation to a French health social insurance
2. Significant congenital disorders that may affect understanding of assessments
3. Patients under guardianship or curatorship

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Quality of life questionnaires	Other: QOL to be completed by the participant; The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between Quality of Life and TICs severity	Severity of the tics measurement (YGTSS Impairment Score) and the quality of life (TS-QOL) between men and women with tic disorders, while controlling for the YGTSS Total Tic Score	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in TICs	Change in tic inventories/tic migrations with the YGTSS tic inventories	6 months

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2021
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: September 22, 2021
• First Submitted That Met QC Criteria: October 11, 2021
• First Posted (Actual): October 25, 2021

Study Record Updates

• Last Update Posted (Estimated): September 4, 2025
• Last Update Submitted That Met QC Criteria: August 27, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurodevelopmental Disorders; Movement Disorders; Tic Disorders
• Other Study ID Numbers: APHP210801

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No